This article was originally published on April 5.
Roche's 454 Life Sciences and NuGen Technologies are collaborating to offer sample preparation and high-throughput sequencing of small and degraded RNA samples, the companies said today.
Under the agreement, the companies will co-promote NuGen's Ovation RNA-Seq system with 454 Life Sciences' GS FLX and GS Junior systems to enable whole-transcriptome profiling of low-abundance samples, the companies said.
More specifically, the companies have developed a method that uses NuGen's proprietary isothermal linear amplification products and the GS FLX Titanium cDNA rapid library preparation protocol for the GS Junior and GS FLX.
The companies said that their collaboration aims to help researchers maximize the use of low-abundance samples, since typical cDNA protocols often require as much as 20 µg of input material.
Combining NuGen's sample prep products with 454's sequencing systems will allow researchers to perform whole-transcriptome profiling on samples with as little as 500 pg of total RNA, NuGen CEO Elizabeth Hutt said in a statement.
"Being able to collaborate with a leading NGS platform provider such as Roche enables customers to leverage NuGen's linear amplification technology while obtaining long and highly accurate sequence reads," Nutt said.
Todd Arnold, vice president of development at 454, added that the combined product offering meets the need of researchers working with precious or irreplaceable samples while allowing them to take advantage of the 454 sequencers' long read lengths, "which are critical for both de novo transcriptome assembly and comprehensive identification of splice variants and fusion transcripts."